| Hani H Salha, MD | |
|
2605 Keiser Blvd, Wyomissing, PA 19610-3338 | |
| (610) 685-8500 | |
| (610) 378-5131 |
| Full Name | Hani H Salha |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 32 Years |
| Location | 2605 Keiser Blvd, Wyomissing, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952391310 | NPI | - | NPPES |
| 0018419410005 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD064194L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Medical Center | Reading, PA | Hospital |
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Penn State Health Community Medical Group Llc | 8729351077 | 646 |
News Archive
A proposal to allow UnitedHealth Group shareholders to make suggestions about executive pay was voted down by the same shareholders it would have empowered at the firm's annual meeting Monday, the Minneapolis Star Tribune reports. The proposal failed with only forty-six percent of shareholders supporting it.
Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.
Alzheimer's disease is the most common dementia worldwide and it is characterized by learning impairment, memory loss, disorientation, and anxiety, among other behavioral and psychological symptoms.
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.
Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
A proposal to allow UnitedHealth Group shareholders to make suggestions about executive pay was voted down by the same shareholders it would have empowered at the firm's annual meeting Monday, the Minneapolis Star Tribune reports. The proposal failed with only forty-six percent of shareholders supporting it.
Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.
Alzheimer's disease is the most common dementia worldwide and it is characterized by learning impairment, memory loss, disorientation, and anxiety, among other behavioral and psychological symptoms.
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.
Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
| Entity Name | Penn State Health Community Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861988644 PECOS PAC ID: 8729351077 Enrollment ID: O20170907002279 |
News Archive
A proposal to allow UnitedHealth Group shareholders to make suggestions about executive pay was voted down by the same shareholders it would have empowered at the firm's annual meeting Monday, the Minneapolis Star Tribune reports. The proposal failed with only forty-six percent of shareholders supporting it.
Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.
Alzheimer's disease is the most common dementia worldwide and it is characterized by learning impairment, memory loss, disorientation, and anxiety, among other behavioral and psychological symptoms.
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.
Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hani H Salha, MD 2605 Keiser Blvd, Wyomissing, PA 19610-3338 Ph: (610) 685-8500 | Hani H Salha, MD 2605 Keiser Blvd, Wyomissing, PA 19610-3338 Ph: (610) 685-8500 |
News Archive
A proposal to allow UnitedHealth Group shareholders to make suggestions about executive pay was voted down by the same shareholders it would have empowered at the firm's annual meeting Monday, the Minneapolis Star Tribune reports. The proposal failed with only forty-six percent of shareholders supporting it.
Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.
Alzheimer's disease is the most common dementia worldwide and it is characterized by learning impairment, memory loss, disorientation, and anxiety, among other behavioral and psychological symptoms.
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months.
Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
Nirav R. Shah, MD, MPH Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1011 Reed Ave, Suite 300, Wyomissing, PA 19610 Phone: 610-374-4401 Fax: 610-374-7140 | |
Dr. David F Steffy, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 950b N Wyomissing Blvd, 3rd Floor, Wyomissing, PA 19610 Phone: 610-898-1820 Fax: 610-372-0164 | |
Dr. Michael Bernard Russo, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2605 Keiser Blvd, Wyomissing, PA 19610 Phone: 610-685-8500 Fax: 610-685-4833 | |
Dr. Pallak Agarwal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2608 Keiser Blvd, Wyomissing, PA 19610 Phone: 610-685-5864 Fax: 610-929-1528 | |
Dr. Kristie Marie Pepper, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2760 Century Blvd, Wyomissing, PA 19610 Phone: 610-375-4251 Fax: 610-685-2870 | |
Louis La Luna, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1011 Reed Ave, Suite 300, Wyomissing, PA 19610 Phone: 610-374-4401 Fax: 610-374-7140 | |
Tara Lynn Dimino, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2605 Keiser Blvd, Wyomissing, PA 19610 Phone: 610-685-8500 Fax: 610-685-4833 |